These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33221266)

  • 21. Accessibility of essential anticancer medicines for children in the Sichuan Province of China.
    Chen Z; Li S; Zou K; Li H; Zeng L; Lu X; Jia ZJ; Cheng G; Zhang L
    Front Public Health; 2022; 10():980969. PubMed ID: 36408013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends and determinants of retail prescription drug costs.
    Teasdale B; Nguyen A; van Meijgaard J; Schulman KA
    Health Serv Res; 2022 Jun; 57(3):548-556. PubMed ID: 35211965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in Retail Prices of Prescription Dermatologic Drugs From 2009 to 2015.
    Rosenberg ME; Rosenberg SP
    JAMA Dermatol; 2016 Feb; 152(2):158-63. PubMed ID: 26606197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reference pricing with endogenous generic entry.
    Brekke KR; Canta C; Straume OR
    J Health Econ; 2016 Dec; 50():312-329. PubMed ID: 27350294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medicine Prices, Availability, and Affordability in Private Health Facilities in Low-Income Settlements in Nairobi County, Kenya.
    Ongarora D; Karumbi J; Minnaard W; Abuga K; Okungu V; Kibwage I
    Pharmacy (Basel); 2019 Apr; 7(2):. PubMed ID: 31022841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Competition on Generic Drug Prices.
    Nguyen NX; Sheingold SH; Tarazi W; Bosworth A
    Appl Health Econ Health Policy; 2022 Mar; 20(2):243-253. PubMed ID: 34904207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physician and Patient Adjustment to Reference Pricing for Drugs.
    Robinson JC; Whaley C; Brown TT; Dhruva SS
    JAMA Netw Open; 2020 Feb; 3(2):e1920544. PubMed ID: 32022881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating access to oral anti-diabetic medicines: A cross-sectional survey of prices, availability and affordability in Shaanxi Province, Western China.
    Yang C; Hu S; Zhu Y; Zhu W; Li Z; Fang Y
    PLoS One; 2019; 14(10):e0223769. PubMed ID: 31618273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean Region.
    Salmasi S; Lee KS; Ming LC; Neoh CF; Elrggal ME; Babar ZD; Khan TM; Hadi MA
    BMC Cancer; 2017 Dec; 17(1):903. PubMed ID: 29282008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
    Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of generic drug prices in seven European countries: a methodological analysis.
    Wouters OJ; Kanavos PG
    BMC Health Serv Res; 2017 Mar; 17(1):242. PubMed ID: 28359273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determinants of drug prices: a systematic review of comparison studies.
    Janssen Daalen JM; den Ambtman A; Van Houdenhoven M; van den Bemt BJF
    BMJ Open; 2021 Jul; 11(7):e046917. PubMed ID: 34266841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
    Levy MS
    Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology.
    Saeed A; Saeed H; Saleem Z; Fang Y; Babar ZU
    PLoS One; 2019; 14(4):e0216122. PubMed ID: 31022276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of Drug Shortages and Association with Generic Drug Prices: A Retrospective Cohort Study.
    Dave CV; Pawar A; Fox ER; Brill G; Kesselheim AS
    Value Health; 2018 Nov; 21(11):1286-1290. PubMed ID: 30442275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pseudo-Generics in South Africa: A Price Comparison.
    Bangalee V; Suleman F
    Value Health Reg Issues; 2019 Sep; 19():87-91. PubMed ID: 31357098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.